• LIVERFASt
  • Patients
  • About us
  • Resources
    • Publications
    • Blog
    • News
    • Brochures
  • Contact us
  • LIVERFASt
  • Patients
  • About us
  • Resources
    • Publications
    • Blog
    • News
    • Brochures
  • Contact us
Portal login

Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)

easlfibronostg on June 29, 2026

Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)

Predictive Value of LIVERFASt, ARFI-FIB-4 to identify chronic Hepatitis B (CHB) — NUH Singapore cohort

easlfibronostg on June 26, 2026

Predictive Value of LIVERFASt, ARFI-FIB-4 to identify chronic Hepatitis B (CHB) — NUH Singapore cohort

Comparative Assessment of NIMs (LIVERFASt/ELF/FIB-4/LSM) in a prospective cohort with chronic liver diseases (Thailand)

easlfibronostg on June 26, 2026

Comparative Assessment of NIMs (LIVERFASt/ELF/FIB-4/LSM) in a prospective cohort with chronic liver diseases (Thailand)

Application of LIVERFASt biomarkers to evaluate longitudinal hepatic fibrosis and inflammation after HCV cure

easlfibronostg on June 26, 2026

Application of LIVERFASt biomarkers to evaluate longitudinal hepatic fibrosis and inflammation after HCV cure

Application of LIVERFASt to predict steatosis in Chronic Hepatitis B patients with metabolic syndrome

easlfibronostg on June 26, 2026

Application of LIVERFASt to predict steatosis in Chronic Hepatitis B patients with metabolic syndrome

US Headquarters

  • 615 Baronne St, Suite 100 New Orleans LA 70113
  • 1-888-552-1603

Asia Headquarters

  • 79 Science Park Drive, Cintech IV, #06-01/08 Singapore 118264
  • + 65 6817 6290
  • service@fibronostics.com
Linkedin Facebook Instagram

Gain insights into your patients’liver health today

© 2026 Fibronostics. All rights reserved.

  • Trust Center
  • Cookie Policy
  • Terms of Use